Salvia Jain is a Hematology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Boston, MA 021142696
Telephone
650-224-0183Provider last certified this registry record 2 Jun 2026.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Acrotech Biopharma Inc.Program year20257 payments
- PFIZER INC.Program year20251 payment
- Secura Bio, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
29.3%Corticosteroid29.3%Prednisone100%Part D<11 patientsDermatology
28.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor28.4%Acyclovir100%Part D≥13 patientsAnti-infectives
17.2%Short-acting sulfonamides17.2%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- Dissecting mechanisms of resistance underlying CD47-SIRPα inhibition in T-cell lymphomas
Massachusetts General Hospital
FY2024$260,116K08CA230498 - Dissecting mechanisms of resistance underlying CD47-SIRPα inhibition in T-cell lymphomas
Massachusetts General Hospital
FY2023$260,116K08CA230498 - Dissecting mechanisms of resistance underlying CD47-SIRPα inhibition in T-cell lymphomas
Massachusetts General Hospital
FY2022$262,116K08CA230498
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”